Optimind Pharma Corp.
OMND
CNSX
| 08/31/2025 | 05/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -22.44% | 4.96% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -22.44% | 4.96% | |||
| Cost of Revenue | 14.67% | -17.58% | |||
| Gross Profit | -37.99% | 18.54% | |||
| SG&A Expenses | -6.51% | -44.41% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.00% | -38.23% | |||
| Operating Income | -570.00% | 106.54% | |||
| Income Before Tax | -3,850.00% | 98.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -3,850.00% | 98.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -3,850.00% | 98.93% | |||
| EBIT | -570.00% | 106.54% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -- | 100.00% | |||
| Normalized Basic EPS | -- | 100.00% | |||
| EPS Diluted | -- | 100.00% | |||
| Normalized Diluted EPS | -- | 100.00% | |||
| Average Basic Shares Outstanding | -1.49% | -4.72% | |||
| Average Diluted Shares Outstanding | -1.49% | -4.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||